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Background: Continuous positive airways pressure (CPAP) for treatment of obstructive sleep
apnea (OSA) can produce troublesome nasal symptoms (i.e. congestion, rhinorrhea) that
may reduce the compliance of CPAP. Topical nasal steroids are often prescribed to reduce
these side effects, although scientific data are scarce supporting any benefits of this treatment
for CPAP-induced nasal side effects.
Objective: To study whether a topical nasal steroid can reduce CPAP-induced nasal symptoms
and improve CPAP adherence during the initial phase of OSA treatment.
Methods: A randomized, double-blinded, placebo-controlled study with fluticasone propionate
100 mg/nasal cavity twice daily Treatment was started 10 days prior to and continued throughout
the first 4 weeks of CPAP. 63 patients who were selected for CPAP treatment participated. Nasal
symptoms were recorded, nasal patency was assessed and lung function was measured with
a peak flow meter. The patients’ adherence to CPAP was recorded by the CPAP device.
Results: Total nasal symptoms increased from baseline to 4 wks after CPAP use for both nasal
treatments (p < 0.05). No differences in total nasal symptoms between treatments were seen
(pZ 1), and no differences in nasal peakflow values after treatmentwere seen (pZ 0.11). More-
over, there were no differences in CPAP use between the treatments.
Conclusion: Fluticasone propionate as a nasal topical steroid does not reduce CPAP-induced
unwantednasal side effects, andhas no beneficial effect onCPAPcompliance during the first four
weeks of treatment in unselected patients with OSAS.
ª 2010 Elsevier Ltd. All rights reserved.1 265 42 94; fax: þ41 61 265 53 53.
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Table 1 Study schedule.
Day 10 Sleep study: establishing OSAS
Day 0 Study inclusion: questionnaires, allergen
testing, peak nasal flow
Night 0 Unattended CPAP titration night (nasal
decongestants)
Day 1 Commence study medication
10 days
Day 11 Start CPAP: nasal mask, fixed pressure
28 days
Day 39 Final assessment: hours of CPAP, symptoms,
peak nasal flow
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Sleep apnea syndrome is defined as having more than five
apnea or hypopnea events lasting longer than 10 s during
1 h of sleep1 and the presence of symptoms. While the term
obstructive sleep apnea (OSA) only indicates that a patient
has an increased apnea hypopnea index (AHI), obstructive
sleep apnea syndrome (OSAS) implicates that a patient
suffers additionally from symptoms such as daytime sleep-
iness, unrefreshing sleep, or other daytime symptoms.
In the Wisconsin Cohort Study, nasal congestion and
rhinitis have been associated with OSA.2 Canova et al.3
showed that patients with OSA have an increased risk of
suffering from perennial allergic rhinitis. OSA patients had
significantly more allergies, especially to house dust mites
compared with matched control subjects. Hence, allergic
rhinitis may also be associated with OSA.
Similarly, McNicholas et al. demonstrated that ragweed
induced rhinitis subjects and the subsequent nasal obstruc-
tion lead to significantly increased numbers of sleep apneas,
increased duration of sleep apneas, and an increase in
arousals in patients not preselected on the basis of sleepi-
ness.4 Similar results, such as an increased number of sleep
apneas and sleep arousals in patients with mechanical
obstruction of the nose e a condition similar to rhinitis-
induced nasal obstruction were found by Craig et al.5
Continuous Positive Airway Pressure (CPAP) treatment is
the standard therapy for moderate to severe OSA. The
positive pressure delivered by the CPAP device makes sure
that the airways do not collapse during sleep and thus
reduces a patient’s AHI.
As in any treatment, patients’ adherence to CPAP is
crucial for its efficient application. Several studies have
investigated the acceptance of CPAP, and the results vary
from 5 to 50% non acceptance. In general it can be esti-
mated that around 20% of patients are not willing to use
a CPAP device. Modern CPAP devices are equipped with
a run-time meter which records how long the device has
been used under pressure, and patient adherence can then
be monitored quite exactly.
Nilius et al.6 show that CPAP treatment causes nasal side
effects. CPAP treatment increases the number of dry noses
when OSA patients are compared before and after the
initiation of CPAP. During the course of CPAP treatment
patients with an AHI of <20 events/h also reported a higher
increase of nasal symptoms, such as congestion and/or
rhinorrhea, than patients with an AHI of >20 events/h.6
Nasal symptoms can influence the CPAP adherence. In
this study we have investigated the effect of a 6-week
treatment with nasal steroids on initial CPAP compliance in
a randomized, placebo-controlled, double-blind, study in
patients with mild to severe OSAS.
Methods
Subjects
Sixty-three patients suffering from moderate to severe OSAS
(AHI > 10 events/h) were recruited to start treatment with
a nasal steroid (fluticasone propionate) or placebo 10 days
prior to and during the first four weeks of CPAP treatment.Study design
Aprospective, randomized,placebo-controlled, doubleblind,
parallel group design was used. Before inclusion a detailed
clinical history was assessed and a physical examination was
performed. Patients also completed a questionnaire about
allergies and nasal symptoms, and underwent a skin prick test
tocommonallergens includinghousedustmites.A spirometric
assessment of the lung function, and a nasal peak flow
measurement was also performed (Youlthen MinieRight Peak
flowmeter7). Table 1 outlines the study flow chart. This study
was conducted in accordance with the principles of “Good
Clinical Practice” (GCP). The study was reviewed and
approvedbytheEthicsCommitteeofBasel (EKBB251/03), and
was also reviewed and approved (“notification”) by the
“SwissMedic” (Nr. 2004 DR 3089).
Definition of OSAS, apnea and hypopnea
All patients were initially seen as outpatients in our Sleep
Disorders Unit, to which they had been referred by their
general practitioners or other referring physicians. The
diagnosis of OSAS was based on a sleep study, either by full
polysomnography, or by limited cardiorespiratory polyg-
raphy. OSAS was defined by the following criteria: (1) apnea
hypopnea index (AHI) > 10 events/h, (2) <25% central
apneas and hypopnea, and (3) age >18 years. Apnea is
defined as an airflow limitation of more than 50% of base-
line followed by saturation drop of at least 4% from baseline
during at least 10 s.8 Hypopnea is defined as a reduction of
airflow by at least 30% and followed by saturation drop of at
least 4% from baseline during at least 10 s8
Definition of allergic rhinitis
We defined allergic rhinitis as having any nasal symptoms
plus any allergies in the skin prick test.9Study treatment assignment
Patients were assigned to study treatment in accordance
with a computerized randomization scheme prepared in
blocks, and in a 1:1 fluticasone propionate 50 mg dose/
placebo ratio. Treatment was 2 puffs in each nostril twice
312 W. Strobel et al.daily giving a total dose of 200 mg/nasal cavity daily.
Patients with OSAS with an AHI > 10 events/h and a history
of daytime somnolence were asked to participate. Patients
with current malignancy or the use of nasal or systemic
steroids within the last four weeks were excluded.
Fig. 1 shows the patient disposition.
CPAP titration
Patients stayed at the hospital for one overnight to assess
the individual CPAP pressure required, with an auto pres-
sure CPAP device. Thereafter a constant pressure CPAP
device was used at the previously defined pressure. The
Patients were given a nasal CPAP mask.
Allergy test
Sensitization to eight allergens was measured by reactions
to skin prick tests on the forearms. Eight allergens were
tested including rye grass pollen, the mould Alternaria
tenuis, the mould Cladosporium homodendron, Artemisia
(“mugwort”), Latex, dog- and cat dander and the house
dust mite Dermatophgoides pteronyssinus (Trimedal AG,
Switzerland). Histamine 10 mg/ml was used as the positive
control and a saline/glycerol solution as the negative
control. After 15 min, wheal size was recorded as the long
axis and its perpendicular. A mean wheal size of 4 mm or
greater was regarded as a positive response. Atopy was
defined as a positive response to at least one of the
allergens tested.
Lung function
Lung function was determined using an EasyOne spirom-
eter (ndd, Zu¨rich). We measured forced vital capacityScreening of 242 patients with 
sleep apnoea
234 potentially eligible patients
63 patients included
32 randomized 
to NTS
31 r
to
10 days study medication +
4 weeks CPAP + study medication
Intention 
to treat 
analysis
Figure 1 Patient disposition chart. NTS: nasal topical(FVC) and 1 s forced expiratory volume (FEV1). The higher
of two readings for FEV1 varying no more than 100 ml was
recorded and the percentage of predicted values10 was
calculated.
Allergy and nasal symptom questionnaire
Nasal symptoms for blocked nose, runny nose, and sneezing
were scored by the patients once daily. These scores were
entered in individual diary cards as follows: 0 Z no symp-
toms, 1 Z mild symptoms, 2 Z moderate symptoms, and
3 Z severe symptoms Then all scores were added up to
a total score, which could range from 0 to 9.11
Nasal peak inspiratory flow
Nasal peak inspiratory flow was assessed with the Youlten
peak inspiratory flow meter.7 Three consecutive measure-
ments were obtained and the best value was recorded.
Measurements were conducted in the sitting position.
Adverse events
Any adverse events during the study were documented in
the patient’s medical records, in accordance with the
investigator’s normal clinical practice, and on the adverse
event page of the clinical record files. The investigator
established a diagnosis of the event based on signs, symp-
toms, and/or other clinical information.
Data collection
Study data were recorded on a case report form. Patients
completed diary cards. The investigator attested his/her
responsibility for the quality of all data recorded and that14: Refused participation
61: treatment with steroids     
3: Urgent indication for 
steroids
49: poor communication
9: lived too far from hospital
9: vacation abroad during 
study
26: additional sleep disorder
andomized 
 placebo
1 lost to follow-up
1 secondary 
exclusion
steroids. CPAP: continuous positive airway pressure.
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each patient’s participation in the study. All data were
entered into a quality-controlled database. The data were
subsequently analyzed according to the methods outlined
in “data analysis”.
Data analysis
The outcome variable was the proportion of subjects in each
group who completed 4 weeks of follow-up with respect to
CPAP compliance:
a) Total hours of using CPAP until the end of the treatment
period
Secondary outcome variableswere possible predictors for
success of a nasal fluticasone propionate treatment such as:
b) Mean hours of using CPAP per night
c) Percentage of patients with any use of CPAP per daySample size calculation
Studies have shown that 20e40% of patients for whom
CPAP was prescribed are non-compliant by the end of one
month.12 The sample size required for a trial that has an
80% chance of detecting, as statistically significant at the
5% level, a true difference between compliance of 20%
between the treatment and placebo group, is 30 patients
in each group.Statistical analysis
Data were analysed using Microsoft Excel Version 2003.
Summary values are arithmetic means and standard devi-
ation. Unpaired t test was used for comparison of contin-
uous variables. Two-sided exact p-values were calculated
to assess differences between categorical variables.
Statistical significance was accepted at the 5% level.Table 2 Comparison of baseline characteristics of NTS and plac
Age (years)
Sex (% male)
BMI (kg/m2)
AHI (events/h)
ESS
Morning nasal symptoms prior to enrollment (0e9)a
Nasal peak inspiratory flow (l/min)
Allergic rhinitis (% of patients)
Mean leakage in titration night (l/min)
Pack years
Currently smoking (% of patients)
FVC (% predicted)
FEV1 (% predicted)
FEV1/FVC
NTSZ nasal topical steroids (fluticasone propionate); BMIZ body mas
Scale; FVC Z forced vital capacity; FEV1 Z forced expiratory volume
a Scores as explained in “nasal symptom questionnaire.”Results
There were no significant differences in baseline charac-
teristics between the nasal topical steroid (NTS) group and
the placebo group (see Table 2).
As shown in Table 3, patients in both groups used the
CPAP device for approximately the same number of days
(p Z 0.73). There was a difference in treatment duration
per night favoring the topical steroid, but this did not reach
statistical significance. The fluticasone propionate group
used the CPAP device about 0.3 h longer compared to the
placebo group (pZ 0.52). We did not find any difference in
CPAP discontinuation rate and reduction of sleepiness
comparing baseline to 4 weeks with CPAP between both
groups either.
During the first phase of the study, patients were already
treated with fluticasone propionate or placebo, although
CPAP treatment had not yet been started. Patients in both
groups showed a reduction of nasal symptoms (blocked
nose, nasal secretion, and sneezing). After four weeks of
CPAP treatment, nasal symptoms increased in both groups
compared to baseline and 10 days of medication. Although
the increase was significant in both comparisons, it was
bigger when comparing 4 weeks of CPAP use to 10 days of
medication (Table 4).
In spite of the significant differences in nasal symptoms
measured during the course of the trial (baseline vs. steroid
use vs. CPAP plus steroid use), the differences between
both groups at the same assessment point were not signif-
icant (Table 5).
There were also no significant differences in peak nasal
inspiratory flow between both groups (Table 6).
Discussion
In our study we found no difference in compliance between
patients who used fluticasone propionate or placebo prior
to, and during, the first 4 weeks of CPAP treatment. Firstly,ebo group.
NTS group Placebo group p-value
52  10 52  13 0.96
25 29 0.72
33  7 30  6 0.06
35  18 34  19 0.77
11.6  3.3 10.6  4.2 0.3
1.1  1.2 1.2  1.5 0.64
116  45 131  44 0.21
10 7 0.76
7.8  1.2 7.2  3.0 0.09
13.0  20.0 13.0  14.9 0.99
16 26 0.33
95.8  14.5 87.6  14.1 0.63
93.2  14.7 94.3  15.1 0.78
97.4  8.7 96.6  7.8 0.72
s index; AHIZ apnea/hypopnea index; ESSZ Epworth Sleepiness
in 1 s; Results as: X  Y, whereas Y Z standard deviation.
Table 5 Comparison of nasal symptoms at each assess-
ment point.
Nasal Symptomsa NTS Placebo p-value
baseline 1.1  1.2 1.2  1.5 0.64
10 days 0.6  1.1 0.5  0.9 0.80
4 wks CPAP 2.5  2.8 2.5  2.6 1.00
CPAP Z continuous positive airway pressure; NTS Z nasal
topical steroids (fluticasone propionate) Results as: X  Y,
whereas Y Z standard deviation.
a Scores as explained in “nasal symptom questionnaire.”
Table 3 Comparison of treatment usage and effective-
ness between NTS and placebo groups.
NTS Placebo p-value
% Days with any use
of CPAP
75.3  25.7 77.4  22.7 0.73
Mean of hours used/
all days
4.3  2.0 4.0  2.2 0.52
Discontinuation % 16.0 19.0 0.70
Δ ESS 2.6  3.3 1.9  3.3 0.42
NTS Z nasal topical steroids (fluticasone propionate);
ESS Z Epworth Sleepiness Scale. Results as: X  Y, whereas
Y Z standard deviation.
314 W. Strobel et al.there were no significant differences in number of hours of
CPAP use per night, secondly the number of days on which
CPAP treatment was used was not significantly different and
thirdly discontinuation of CPAP during our trial did not
significantly differ between the groups. Fourthly, we also
found no significant difference in improving daytime sleep-
iness, measured using the Epworth Sleepiness Scale, in
patients using either fluticasone propionate or placebo. We
therefore conclude that the use of fluticasone propionate
had no effect on CPAP compliance during the initial 4 weeks
of treatment in an unselected group of patients with OSAS.
However, we cannot rule out that there might be a signifi-
cant difference when using topical nasal steroids for 3 month
or longer.
A study done by Krieger et al. examined CPAP compliance
in 728 Patients with sleep apnea (AHI > 15 events/h). After
a mean follow-up time of 1176  38 days (27e4203 days),
the mean rate of CPAP use was 5.7  1.8 h/day in OSA
patients.13 In our study the patients had AHIs ranging from 8
events/h up to 86 events/h (mean 34.2  18.7), but we only
reached a mean compliance of 4.3 h/day in the NTS group
and 4.0 h/day in the placebo group. Since our patients had
a mean AHI of 34.2 events/h, thus suffering from severe
OSA, a higher compliance could have been expected. As
previously mentioned, a mean CPAP use of 4 h/day is
required for patients to be considered compliant and our
study just meets this requirement. Since we only tracked
the first 4 weeks of CPAP treatment, it is possible that the
patients’ compliance would increase after this initial
period, when they get used to using the device regularly.Table 4 Comparison of nasal symptoms during the course of th
Nasal Symptoms* Baseline
Placebo 1.2  1.5
p Z 0.02
NTS 1.1  1.2
p Z 0.09
CPAP Z continuous positive airway pressure; NTS Z nasal topica
Y Z standard deviation; *Scores as explained in “nasal symptom queSince CPAP treatment is known to cause nasal symptoms
(e.g. congestion, rhinorrhea) patients commencing with
CPAP treatment are often given nasal topical steroids.
Steroid therapy has two uses in OSA patients. Firstly,
a study done by Kiely et al.14 found a significant reduction
of the AHI under intranasal corticosteroid therapy in
patients suffering from OSA. On the other hand, a system-
atic review done by Smith et al.,15 states that studies of
longer duration are required to determine the actual
benefit. Secondly, nasal topical steroids (e.g. fluticasone
propionate) would be expected to counteract the nasal
inflammation caused by allergic rhinitis and/or CPAP
treatment. Although we found no significant reduction of
nasal symptoms in patients using nasal topical steroids
compared to placebo, there are other studies suggesting
the opposite. Craig et al. showed a significant improvement
in subjective sleep quality in patients under nasal cortico-
steroid therapy suffering from nasal congestion due to
allergic rhinitis.5 Our study, however, was not powered to
perform subgroup analysis of patients having OSAS and
allergic rhinitis. Therefore, we cannot rule out that
patients who suffer from perennial rhinitis and are in need
of nasal CPAP therapy might benefit from a topical nasal
steroid treatment.
A study done by Shadan et al.16 found no increase in nasal
symptom scores independently of the compliance to CPAP
therapy. Neither did they find symptoms of rhinitis prior to
CPAP therapy to be a risk for noncompliance. However, a high
neutrophil count in the nasal smear of patients before CPAP
therapy, although they didn’t show any symptoms of rhinitis,
appeared to be a risk factor for discontinuation of the CPAP
therapy. This suggests that there may be a low gradee trial.
10 days 4 wks CPAP
0.5  0.9 2.5  2.6
p < 0.01
p < 0.03
0.6  1.1 2.5  2.8
p < 0.01
p < 0.02
l steroids (fluticasone propionate) Results as: X  Y, whereas
stionnaire.”
Table 6 Comparison of peak nasal inspiratory flow in
patients using nasal topical steroids or placebo at baseline
and after 4 weeks of CPAP use.
Peak nasal insp.
Flow (l/min)
NTS Placebo p-value
Baseline 116.3  45.6 130.6  44.3 0.21
CPAP 119.0  48.7 141.0  54.5 0.11
CPAP Z continuous positive airway pressure; NTS Z nasal
topical steroids (fluticasone propionate) Results as: X  Y,
whereas Y Z standard deviation.
Effects of topical nasal steroids on OSAS use 315subclinical inflammation in these patients, which worsens
during CPAP therapy. These discrepant results might be due
to the different patient populations in the various studies. In
our studyweused an unselected group of patientswithOSAS,
while the study by Craig et al.,5 mentioned previously,
examined patients suffering from allergic rhinitis. Thus, it
can be hypothesized that only patients suffering from
allergic rhinitismaybenefit fromnasal topical steroids during
the initiation of CPAP treatment.
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